🔴 Revolution Medicines is trading 4.62% down; no clear catalyst identified

Revolution Medicines is trading at $191.59, down 4.62%, with no clear company-specific catalyst identified for October 8.

• The latest identified company update was the October 5 start of patient treatment in a Phase 3 trial, which predates the decline.
• Broader markets faced pressure from rising oil prices and elevated Treasury yields, but supplied index moves do not establish these as the direct cause.